ENGLEWOOD, Colo., Feb. 14,
2019 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI),
an innovative medical technology company specializing in the
manufacture and sale of non-invasive medical devices for pain
management, stroke rehabilitation, cardiac monitoring and
neurological diagnostics, announces that it will be ringing the
Nasdaq Opening Bell at Times Square in New York on Thursday,
February 21, 2019.
The ceremony commemorates Zynex's listing on
the Nasdaq Capital Market on February 21, 2019. Thomas
Sandgaard, Founder, Chairman and CEO is pleased to celebrate
alongside Zynex's Board of Directors and members of the executive
team honoring the Company's milestone achievement.
"The uplisting to Nasdaq is a milestone achievement for the
Company, and one that we believe presents the opportunity for
exposure to a broader and more diverse investor audience," said Mr.
Sandgaard. "We would like to take this moment to thank and
acknowledge the employees and investors who have supported the
Company and helped facilitate the day."
The ceremony will be held at Nasdaq's MarketSite in
New York City and will be webcast
live on February 21, 2019, at
9:15 a.m. (Eastern Time) at
https://new.livestream.com/nasdaq/live. In addition, photos and
video of the Nasdaq Bell Ringing Ceremony will be available,
courtesy of the Nasdaq, on Facebook (Nasdaq), Twitter (@Nasdaq),
and YouTube.
About Zynex, Inc.
Zynex, founded in 1996, markets and sells its own design of
electrotherapy medical devices used for pain management and
rehabilitation; and the company's proprietary NeuroMove device
designed to help recovery of stroke and spinal cord injury
patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers. For additional information,
please visit: www.zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or
projections and as such are subject to numerous risks and
uncertainties. The company makes no express or implied
representation or warranty as to the completeness of this
information or, in the case of projections, as to their
attainability or the accuracy and completeness of the assumptions
from which they are derived. Actual results may vary significantly
from the results expressed or implied in such statements. Factors
that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain FDA clearance and CE marking of new products, the
acceptance of new products as well as existing products by doctors
and hospitals, larger competitors with greater financial resources,
the need to keep pace with technological changes, our dependence on
the reimbursement for our products from health insurance companies,
our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31,
2017 as well as Forms 10-Q, 8-K and 8-K/A, press releases and
the Company's website.
Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-to-ring-the-nasdaq-stock-market-opening-bell-to-celebrate-its-listing-300795619.html
SOURCE Zynex, Inc.